[PDF] Top 20 Personality changes in Alzheimer's disease
Has 10000 "Personality changes in Alzheimer's disease" found on our website. Below are the top 20 most common "Personality changes in Alzheimer's disease".
Personality changes in Alzheimer's disease
... assess personality change in AD subjects (Rubin et ...Item s which mostly fall within the Extroversion factor and hence will be looked at ...such personality-related behaviours occur very early in ... See full document
175
Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel
... including Alzheimer ’ s ...and personality changes, as well as cognitive impairments, CTE is increasingly categorized as an acquired frontotem- poral lobar ... See full document
11
ALZHEIMER’S DISEASE: A REVIEW
... Alzheimer's disease clinical feature typically presents with early problems in memory and visuospatial abilities (eg, becoming lost in familiar surroundings, inability to copy a geometric design on paper), yet ... See full document
9
Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort
... ’ s disease (AD) is the leading cause of demen- tia worldwide and has been the target of clinical trials and intervention studies for many years ...the Alzheimer ’ s Disease Assessment ... See full document
13
Biochemical changes in alzheimer’s disease: an overview
... Dementia in the elderly population is most commonly caused by Alzheimer’s disease (AD). The characteristic features of AD are the appearance of extracellular amyloid-β (Aβ) plaques and neurofibrillary tangles ... See full document
5
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
... developing disease, many of the grey areas in sporadic AD research are ...cular disease and diabetes) that can confound AD diagnosis and outcomes in late-onset, sporadic ...clinical changes to be ... See full document
7
Cognitive reserve and clinical progression in Alzheimer diseaseA paradoxical relationship
... cognitive changes may be harder to capture over shorter follow-up durations, this could have caused a bias towards the detection of CR effects in participants who were less ... See full document
14
Imago Mundi, Imago AD, Imago ADNI
... pathological changes characteristic of the dis- ease are already present at the preclinical and prodromal stages, eventually leading to the postulation of new diag- nostic criteria based on markers of pathology ... See full document
10
The genetics of Alzheimer's disease
... sequencing is a widely used technology, but it has limitations in terms of cost, speed, and efficacy. High-throughput or NGS technologies are recent hot topics in genomic research of animals and humans. NGS technologies ... See full document
17
SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment
... on changes in our primary outcome: global cognitive function measured using the Alzheimer Disease Assessment Scale Cognitive 13 and the plus modality (ADAS-Cog 13 and ...plus). Changes in the ... See full document
15
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?
... advanced disease progression were excluded from the present study; disease duration measured as time since first notice of symptoms was documented by caregivers and in clinical records of all ...mild ... See full document
12
COGNITIVE CHANGES AND BASAL THYROTROPIN IN TREATED AND UNTREATED PATIENTS WITH ALZHEIMER S DISEASE
... cognitive changes (measured with the Mini-Mental Status Examination questionnaire; MMSE) and baseline thyrotropin (TSH) levels in 17 patients treated with cholinesterase inhibitors (Group A), 16 patients treated ... See full document
5
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
... AD: Alzheimer ’ s disease; APOE: Apolipoprotein E; ARMWS: Age-related white matter changes scale; A β : Amyloid- β ; BBACL: BioBank Alzheimer Center Limburg; CSF: Cerebrospinal fluid; ... See full document
10
Disease-modifying drugs in Alzheimer's disease
... June 2012. The first study compared 0.5 mg/kg and 1 mg/kg of bapineuzumab versus placebo. The second compared responses to bapineuzumab 0.5 mg/kg versus placebo in ApoE ε 4 carriers. Coprimary endpoints for each trial ... See full document
9
Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
... Aβ42, tau, and ptau are important biomarkers for Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) levels of amyloid-beta (Aβ) and tau change before clin- ical symptoms of AD are observed. Aβ42 is decreased in ... See full document
9
Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set
... There is limited serial quantitated MRI data available from NACC, and it will be essential to leverage the NACC data set in the future to examine changes in WMH and its correspondence to neuropsychological, ... See full document
13
The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group
... Discussion of current evidence Impairments in in- strumental activities of daily living (IADL) influence everyday lives of patients and caregivers, and are es- sential for the planning of care needs and for legal and ... See full document
15
For debate: substituting placebo controls in long-term Alzheimer's prevention trials
... ’ s per- formance scores on the ADAScog 24 months after their baseline examination - and a multivariate (trajectory- related) approach - that is, an algorithm that forecasts the decline of performance during 36 ... See full document
11
Glutamate receptors function as scaffolds for the regulation of β-amyloid and cellular prion protein signaling complexes
... based on sequence homology, G protein-coupling spe- cificity and pharmacological profile [38]. The Group I mGluRs, mGluR1a and mGluR5a activate phospholipase C to generate both inositol 1,4,5 trisphosphate and diac- ... See full document
9
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
... In our view, resolving the apparent contradictions in evidence begins with abandoning the assumption that FAD and late onset AD are etiologically comparable. Doing so will help create the right context for the study of ... See full document
5
Related subjects